http://www.cnr.it/ontology/cnr/individuo/prodotto/ID181405

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia (Articolo in rivista)

Type

Articolo in rivista (Classe)
Prodotto della ricerca (Classe)

Label

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia (Articolo in rivista) (literal)

Anno

2011-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

10.1186/1476-511X-10-185 (literal)

Alternative label

Mariarita Puntoni 1, Francesco Sbrana 2, Federico Bigazzi 2, Fabrizio Minichilli 1, Ezio Ferdeghini 1, Tiziana Sampietro 1,2 (2011)
Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
in Lipids in health and disease
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Mariarita Puntoni 1, Francesco Sbrana 2, Federico Bigazzi 2, Fabrizio Minichilli 1, Ezio Ferdeghini 1, Tiziana Sampietro 1,2 (literal)

Pagina inizio

1 (literal)

Pagina fine

8 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

ID_PUMA: cnr.ifc/2011-A0-115 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

http://www.lipidworld.com/content/10/1/185 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

10 (literal)

Rivista

Lipids in health and disease (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

8 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

185 (literal)

Note

ISI Web of Science (WOS) (literal)
Scopu (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1 CNR Institute of Clinical Physiology; via Moruzzi n° 1, Pisa, Italy; 2 Fondazione \"Gabriele Monasterio\" CNR - Regione Toscana; via Moruzzi n° 1, Pisa, Italy. (literal)

Titolo

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia (literal)

Abstract

Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease. Methods Since hypercholesterolemia is associated with atherosclerosis and inflammation, we tested whether MPO serum levels were up-regulated in Familial Hypercholesterolemia (FH) and whether acute reduction of total cholesterol (TC) would also reduce MPO concentration. FH subjects undergoing LDL-apheresis (LDL-A) treatment are a paradigmatic clinical model where TC rapidly plunges from extremely high to extremely low levels after selective LDL removal, and then spontaneously rebounds to baseline conditions. This clinical setting allows multiple intra-patient observations at different plasma TC concentrations. We measured MPO levels in serum by ELISA tests, and in peripheral leukocytes by immunofluorescence, to learn whether they were affected by the changes in TC levels. Serum MPO was measured before and serially up to the 14th day following LDL-A. Results In both serum and peripheral leukocytes, MPO concentrations were i) higher than in sex- and age-matched healthy controls (p < 0.01); ii) decreased with TC reduction; iii) parallel with TC time course; iv) correlated with plasma TC. At regression analysis, plasma TC was the only variable considered that influenced MPO serum levels (? 0.022 ± 0.010, p < 0.0001). Conclusions In FH the MPO serum levels were modulated through changes in the TC concentrations carried out by LDL-A. Further study is needed to determine whether reduced MPO levels obtained by LDL-A could have any therapeutic impact. Myeloperoxidase; Familial Hypercholesterolemia (FH); LDL-apheresis; plaque vulnerability; peripheral leukocytes; total cholesterol (literal)

Prodotto di